CME Group (CME) Stock Forecast & Price Target

Q: What analysts cover CME Group?

CME Group has been rated by research analysts at Barclays , CLSA , Deutsche Bank , JPMorgan Chase & Co. , Morgan Stanley , Piper Sandler , TD Cowen , UBS Group , Weiss Ratings , and Wells Fargo & Company in the past 90 days.

$317.97 +2.47 (+0.78%)

Closing price 11/13/2026 04:00 PM Eastern

Extended Trading

$317.20 -0.78 (-0.24%)

As of 11/13/2026 07:51 PM Eastern

Compare

CME Group - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Hold

Based on 18 Analyst Ratings

Sell
2

Hold
6

Buy
10

Based on 18 Wall Street analysts who have issued ratings for CME Group in the last 12 months, the stock has a consensus rating of "Hold." Out of the 18 analysts, 2 have given a sell rating, 6 have given a hold rating, and 10 have given a buy rating for CME.

Consensus Price Target

$314.44
-1.11% Downside

According to the 18 analysts' twelve-month price targets for CME Group, the average price target is $314.44. The highest price target for CME is $367.00, while the lowest price target for CME is $230.00. The average price target represents a forecasted downside of -1.11% from the current price of $317.97.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for CME and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for CME Group and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CME Analyst Ratings Over Time

Type	Current Forecast 11/14/25 to 11/14/26	1 Month Ago 10/15/25 to 10/15/26	3 Months Ago 8/16/25 to 8/16/26	1 Year Ago 11/14/24 to 11/14/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	10 Buy rating(s)	9 Buy rating(s)	10 Buy rating(s)	8 Buy rating(s)
Hold	6 Hold rating(s)	6 Hold rating(s)	5 Hold rating(s)	7 Hold rating(s)
Sell	2 Sell rating(s)	3 Sell rating(s)	3 Sell rating(s)	3 Sell rating(s)
Consensus Price Target	$314.44	$292.94	$291.81	$287.65
Forecasted Upside	-1.11% Downside	1.20% Upside	8.16% Upside	0.91% Upside
Consensus Rating	Hold	Hold	Hold	Hold

CME Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CME Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

CME Group Stock vs. The Competition

Type	CME Group	Finance Companies	Broader Market
Consensus Rating Score	2.44	2.27	2.52
Consensus Rating	Hold	Hold	Moderate Buy
Predicted Upside	-1.11% Downside	32.35% Upside	14.68% Upside
News Sentiment Rating	Positive News See Recent CME News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Show

Rating

Upside/Downside

Action

Report Date

0 Results

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
10/23/2026	Weiss Ratings 2 of 5 stars		Upgrade	Buy (B-) ➝ Buy (B)
10/22/2026	Piper Sandler 2 of 5 stars	Patrick Moley 3 of 5 stars	Reiterated Rating	Overweight	$295.00 ➝ $330.00	+11.57%
10/22/2026	Wells Fargo & Company 3 of 5 stars	Daniel Welden Not Rated	Boost Target	Overweight	$315.00 ➝ $333.00	+12.58%
10/22/2026	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Michael Cyprys Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Overweight	$337.00 ➝ $359.00	+21.37%
10/22/2026	CLSA Subscribe to MarketBeat All Access to unlock brokerage rankings		Set Target		$367.00	+24.07%
10/22/2026	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Benjamin Budish Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Equal Weight	$281.00 ➝ $321.00	+8.52%
10/22/2026	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Alex Kramm Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Neutral	$270.00 ➝ $310.00	+1.52%
10/22/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Kenneth Worthington Subscribe to MarketBeat All Access to unlock analyst rankings	Upgrade	Underweight ➝ Overweight	$367.00	+24.07%
10/5/2026	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Bill Katz Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Buy	$292.00 ➝ $300.00	+13.43%
8/19/2026	Deutsche Bank Subscribe to MarketBeat All Access to unlock brokerage rankings	Brian Bedell Subscribe to MarketBeat All Access to unlock analyst rankings	Downgrade	Buy ➝ Hold	$286.00 ➝ $270.00	-0.57%
Get the Latest News and Ratings for CME and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for CME Group and its competitors with MarketBeat's FREE daily newsletter.
7/23/2026	Bank of America Subscribe to MarketBeat All Access to unlock brokerage rankings	Craig Siegenthaler Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Underperform	$226.00 ➝ $230.00	-9.25%
7/2/2026	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Patrick O'Shaughnessy Subscribe to MarketBeat All Access to unlock analyst rankings	Reiterated Rating	Outperform	$320.00	+35.65%
6/30/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings		Lower Target	Sell	$267.00 ➝ $245.00	+9.36%
6/18/2026	Keefe, Bruyette & Woods Subscribe to MarketBeat All Access to unlock brokerage rankings	Chris Allen Subscribe to MarketBeat All Access to unlock analyst rankings	Upgrade	Market Perform ➝ Outperform	$305.00	+20.77%
6/11/2026	Rothschild & Co Redburn Subscribe to MarketBeat All Access to unlock brokerage rankings	Simon Clinch Subscribe to MarketBeat All Access to unlock analyst rankings	Upgrade	Neutral ➝ Buy	$316.00 ➝ $323.00	+22.44%
6/5/2026	Erste Group Bank Subscribe to MarketBeat All Access to unlock brokerage rankings		Downgrade	Buy ➝ Hold
4/9/2026	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings		Lower Target	Buy	$356.00 ➝ $349.00	+16.34%
3/4/2026	Argus Subscribe to MarketBeat All Access to unlock brokerage rankings	Stephen Biggar Subscribe to MarketBeat All Access to unlock analyst rankings	Downgrade	Buy ➝ Hold
2/5/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Ashish Sabadra Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Sector Perform	$295.00 ➝ $302.00	+2.50%
9/25/2025	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Christopher Allen Subscribe to MarketBeat All Access to unlock analyst rankings	Upgrade	Neutral ➝ Buy	$275.00 ➝ $300.00	+13.45%
7/24/2025	Oppenheimer Subscribe to MarketBeat All Access to unlock brokerage rankings	Owen Lau Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Outperform	$300.00 ➝ $303.00	+9.30%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 08:12 PM ET.

Should I Buy CME Group Stock? CME Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, November 13, 2026. Please send any questions or comments about these CME Group pros and cons to contact@marketbeat.com.

CME Group
Bull Case

Here are some ways that investors could benefit from investing in CME Group Inc.:

CME Group Inc. is currently trading at $317.97, a price that reflects a significant recovery from its 52-week low of $218.31 and positions the stock near its 52-week high of $329.16, indicating strong recent momentum and investor confidence in the company's performance.
The company demonstrated robust financial health in its most recent quarter, reporting earnings per share of $3.02, which beat the consensus estimate of $2.99, while revenue grew 10.6% year-over-year to $1.74 billion, showcasing the effectiveness of its business model in generating consistent growth.
With a beta of 0.15, CME Group Inc. exhibits extremely low volatility compared to the broader market, making it a defensive investment that can provide stability to a portfolio during periods of market uncertainty or economic downturns.
Institutional investors are showing renewed interest in the stock, with Russell Investments Group Ltd. increasing its holdings by 7.6% and Eurizon Capital SGR S.p.A. boosting its stake by over 1,000% in the third quarter, suggesting that large funds are recognizing the company's long-term value and stability.
The company offers a dividend yield of 1.65% with a payout ratio of 42.66%, providing a steady income stream for investors while maintaining a conservative approach to capital distribution that supports future growth and financial resilience.

CME Group
Bear Case

Investors should be bearish about investing in CME Group Inc. for these reasons:

The stock carries a price-to-earnings ratio of 26.08, which is relatively high and may indicate that the current valuation is stretched, leaving little room for error if future earnings growth slows or if market sentiment shifts negatively.
Corporate insiders have been net sellers recently, with Julie Winkler selling 10,079 shares and Director Howard J. Siegel selling 2,000 shares in early November, which could signal a lack of confidence from those with the most intimate knowledge of the company's operations.
Despite recent positive news, the consensus rating from analysts remains a "Hold" with a target price of $314.44, which is slightly below the current stock price of $317.97, suggesting that the stock may be fully valued or even slightly overvalued relative to professional estimates.
Short interest has been fluctuating, with a recent increase to 5,351,351 shares shorted as of October 30, 2026, indicating that some market participants are betting against the stock, which could lead to increased volatility or downward pressure if the trend continues.
The company's debt-to-equity ratio of 0.13, while low, is not zero, and in a rising interest rate environment, any increase in borrowing costs could impact the company's bottom line, although this risk is mitigated by its strong cash flow and market position.

CME Forecast - Frequently Asked Questions

According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for CME Group is $314.44, with a high forecast of $367.00 and a low forecast of $230.00.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CME Group in the last year. There are currently 2 sell ratings, 6 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CME shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CME, but not buy additional shares or sell existing shares.

According to analysts, CME Group's stock has a predicted downside of -1.11% based on their 12-month stock forecasts.

Over the previous 90 days, CME Group's stock had 3 upgrades and 1 downgrade by analysts.

CME Group has been rated by research analysts at Barclays, CLSA, Deutsche Bank, JPMorgan Chase & Co., Morgan Stanley, Piper Sandler, TD Cowen, UBS Group, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like CME Group more than other "finance" companies. The consensus rating score for CME Group is 2.44 while the average consensus rating score for "finance" companies is 2.27. Learn more on how CME compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With CME Group Recommendations

MarketBeat monitors more than a dozen sources for CME Group analyst ratings, with the most recent rating issued on 10/23/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CME Group (CME) Stock Forecast & Price Target